{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:52:05Z","timestamp":1784735525251,"version":"3.55.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>We reported a case of a 31-year-old female with therapy-resistant, refractory, and metastatic luminal B breast cancer. Using organoids derived from the patient\u2019s malignant pleural effusion for drug screening, we found that the combination of gemcitabine and cisplatin was the most sensitive, considering both IC50 and AUC values. In clinical practice, it was observed that the patient responded well to the selected treatment regimen, resulting in a significant reduction of pleural effusions, a marked decrease in tumor markers (e.g., CA125), and improved performance status (PS 2\u21921). The organoid model enabled the rational use of the patient\u2019s metabolic waste. It replicates the complexity of human tumors and facilitates extensive screening of beneficial drugs for patient diseases, particularly those with advanced tumors showing heterogeneity and rapid disease progression. This method swiftly identifies the optimal therapeutic drug regimen, minimizing the risk of drug resistance and trial costs, thereby providing maximum patient benefits<\/jats:p>","DOI":"10.3389\/fonc.2025.1630761","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T04:10:35Z","timestamp":1759723835000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Patient-derived organoid-guided precision therapy for a very young woman with multidrug-resistant metastatic breast cancer: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Xiaonuo","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2017.07.017","article-title":"ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3)","volume":"35","author":"Paluch-Shimon","year":"2017","journal-title":"Breast"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-3983-9","article-title":"Long-term outcome in young women with breast cancer: a population-based study","volume":"160","author":"Fredholm","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0293830","DOI":"10.1371\/journal.pone.0293830","article-title":"Metastasis, characteristic, and treatment of breast cancer in young women and older women: A study from the Surveillance, Epidemiology, and End Results registration database","volume":"18","author":"Gao","year":"2023","journal-title":"PloS One"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0142(20000315)88:6<1393::aid-cncr17>3.0.co;2-p","article-title":"Frequency of BRCA1\/BRCA2 mutations in a population-based sample of young breast carcinoma cases","volume":"88","author":"Malone","year":"2000","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061917","article-title":"What is known about breast cancer in young women","volume":"15","author":"Zhu","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw6985","article-title":"Cancer modeling meets human organoid technology","volume":"364","author":"Tuveson","year":"2019","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-020-0379-4","article-title":"Establishment of patient-derived cancer organoids for drug-screening applications [published correction appears in Nat Protoc. 2021 Dec;16(12):5739. doi: 10.1038\/s41596-021-00494-5","volume":"15","author":"Driehuis","year":"2020","journal-title":"Nat Protoc"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e2101176","DOI":"10.1002\/advs.202101176","article-title":"Patient-derived organoids can guide personalized-therapies for patients with advanced breast cancer","volume":"8","author":"Chen","year":"2021","journal-title":"Adv Sci (Weinh)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bty560","article-title":"fastp: an ultra-fast all-in-one FASTQ preprocessor","volume":"34","author":"Chen","year":"2018","journal-title":"Bioinformatics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2514","article-title":"Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/978-3-030-91836-1_3","article-title":"Somatic and Germline Variant Calling from Next-Generation Sequencing Data","volume-title":"Computational Methods for Precision Oncology","author":"Chang","year":"2022"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/biomethods\/bpaf012","article-title":"Optimizing drug sensitivity assays in patient-derived tumor organoids: a comparison of IC50 estimation methods and experimental parameters","volume":"10","author":"Chen","year":"2025","journal-title":"Biol Methods Protoc"},{"key":"B15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/CM9.0000000000001814","article-title":"Global and regional trends in incidence and mortality of female breast cancer and associated factors at national level in 2000 to 2019","volume":"135","author":"Luo","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10549-021-06236-1","article-title":"Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer","volume":"187","author":"Shah","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.3754","article-title":"Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea\u2013a report from the Korean Breast Cancer Society","volume":"25","author":"Ahn","year":"2007","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.658395","article-title":"Pleural fluid has pro-growth biological properties which enable cancer cell proliferation","volume":"11","author":"Asciak","year":"2021","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107542","article-title":"Establishing mesothelioma patient-derived organoid models from Malignant pleural effusions","volume":"191","author":"Hocking","year":"2024","journal-title":"Lung Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1630761\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T04:10:35Z","timestamp":1759723835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1630761\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":19,"alternative-id":["10.3389\/fonc.2025.1630761"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1630761","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"article-number":"1630761"}}